Denali Therapeutics (DNLI) Competitors $14.70 +0.24 (+1.66%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$14.90 +0.20 (+1.33%) As of 08/15/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DNLI vs. BEAM, ROIV, GRFS, LEGN, RVMD, RYTM, RNA, NUVL, AXSM, and CRSPShould you be buying Denali Therapeutics stock or one of its competitors? The main competitors of Denali Therapeutics include Beam Therapeutics (BEAM), Roivant Sciences (ROIV), Grifols (GRFS), Legend Biotech (LEGN), Revolution Medicines (RVMD), Rhythm Pharmaceuticals (RYTM), Avidity Biosciences (RNA), Nuvalent (NUVL), Axsome Therapeutics (AXSM), and CRISPR Therapeutics (CRSP). These companies are all part of the "pharmaceutical products" industry. Denali Therapeutics vs. Its Competitors Beam Therapeutics Roivant Sciences Grifols Legend Biotech Revolution Medicines Rhythm Pharmaceuticals Avidity Biosciences Nuvalent Axsome Therapeutics CRISPR Therapeutics Beam Therapeutics (NASDAQ:BEAM) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation. Do institutionals and insiders have more ownership in BEAM or DNLI? 99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are held by institutional investors. 3.5% of Beam Therapeutics shares are held by insiders. Comparatively, 12.5% of Denali Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media prefer BEAM or DNLI? In the previous week, Denali Therapeutics had 21 more articles in the media than Beam Therapeutics. MarketBeat recorded 32 mentions for Denali Therapeutics and 11 mentions for Beam Therapeutics. Denali Therapeutics' average media sentiment score of 0.46 beat Beam Therapeutics' score of 0.34 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 0 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Denali Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, BEAM or DNLI? Beam Therapeutics has a beta of 2.22, indicating that its share price is 122% more volatile than the S&P 500. Comparatively, Denali Therapeutics has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Do analysts recommend BEAM or DNLI? Beam Therapeutics presently has a consensus price target of $48.45, suggesting a potential upside of 171.91%. Denali Therapeutics has a consensus price target of $33.85, suggesting a potential upside of 130.25%. Given Beam Therapeutics' higher probable upside, equities research analysts clearly believe Beam Therapeutics is more favorable than Denali Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Beam Therapeutics 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 3 Strong Buy rating(s) 3.07Denali Therapeutics 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 3 Strong Buy rating(s) 3.12 Is BEAM or DNLI more profitable? Denali Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -661.31%. Denali Therapeutics' return on equity of -40.79% beat Beam Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Beam Therapeutics-661.31% -43.15% -31.06% Denali Therapeutics N/A -40.79%-36.39% Which has higher earnings and valuation, BEAM or DNLI? Beam Therapeutics has higher revenue and earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeam Therapeutics$63.52M28.38-$376.74M-$4.50-3.96Denali TherapeuticsN/AN/A-$422.77M-$2.80-5.25 SummaryDenali Therapeutics beats Beam Therapeutics on 8 of the 15 factors compared between the two stocks. Get Denali Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DNLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNLI vs. The Competition Export to ExcelMetricDenali TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.11B$3.10B$5.69B$9.81BDividend YieldN/A2.23%3.79%4.07%P/E Ratio-5.2520.8931.0825.11Price / SalesN/A363.22466.03115.16Price / CashN/A42.3037.4059.05Price / Book2.098.659.096.18Net Income-$422.77M-$54.65M$3.26B$265.11M7 Day Performance5.30%6.56%7.31%4.20%1 Month Performance-1.14%7.53%5.43%2.00%1 Year Performance-36.14%13.69%30.60%23.76% Denali Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNLIDenali Therapeutics4.1682 of 5 stars$14.70+1.7%$33.85+130.2%-37.9%$2.11BN/A-5.25430Trending NewsEarnings ReportAnalyst RevisionBEAMBeam Therapeutics2.3272 of 5 stars$17.17-2.6%$48.45+182.2%-28.3%$1.74B$63.52M-3.82510News CoverageROIVRoivant Sciences2.9271 of 5 stars$11.17-2.8%$16.50+47.7%+4.8%$7.59B$29.05M-44.68860Gap DownGRFSGrifols3.7068 of 5 stars$10.60-0.6%$10.30-2.8%+54.0%$7.29B$7.81B9.0623,822Ex-DividendShort Interest ↑LEGNLegend Biotech3.746 of 5 stars$36.24-2.1%$73.33+102.4%-32.7%$6.66B$728.30M-61.422,609News CoverageEarnings ReportAnalyst ForecastRVMDRevolution Medicines4.162 of 5 stars$34.70-0.9%$68.82+98.3%-16.5%$6.49B$11.58M-7.71250News CoverageAnalyst ForecastRYTMRhythm Pharmaceuticals3.7672 of 5 stars$94.31+2.5%$101.57+7.7%+109.0%$6.26B$130.13M-31.33140News CoverageInsider TradeRNAAvidity Biosciences2.9428 of 5 stars$45.75-1.2%$67.00+46.4%+2.2%$5.51B$8.93M-15.25190Insider TradeNUVLNuvalent3.1743 of 5 stars$74.95+1.1%$119.60+59.6%+5.7%$5.38BN/A-15.3040AXSMAxsome Therapeutics4.6769 of 5 stars$103.96-0.8%$178.00+71.2%+27.6%$5.19B$385.69M-20.50380CRSPCRISPR Therapeutics3.3408 of 5 stars$55.41+0.7%$71.60+29.2%+22.3%$5.04B$37.31M-10.20460 Related Companies and Tools Related Companies Beam Therapeutics Competitors Roivant Sciences Competitors Grifols Competitors Legend Biotech Competitors Revolution Medicines Competitors Rhythm Pharmaceuticals Competitors Avidity Biosciences Competitors Nuvalent Competitors Axsome Therapeutics Competitors CRISPR Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DNLI) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored"I'm risking my reputation on this"A massive supply shock is building in the crypto market that could send Bitcoin to $300,000 this year. That...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Denali Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access